Crispr Therapeutics AG stock analysis
Crispr Therapeutics AG (1CG) Stock Price & Analysis
1CG Stock Chart & Stats
- Day’s Range
- CHF 37.95 - CHF 39.80
- 52-Week Range
- CHF 37.95 - CHF 52.00
- Previous Close
- CHF 39.80
- Volume
- N/A
- Average Volume (3M)
- 171
- Market Cap
- CHF 3.64B
- Enterprise Value
- CHF 3.86B
- Total Cash (Recent Filing)
- CHF 2.27B
- Total Debt (Recent Filing)
- CHF 779.83M
- Price to Earnings (P/E)
- ―
- Beta
- 0.19
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- -0.97
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
CRISPR Gene-Editing Platform
A focused CRISPR/Cas9 platform and broad therapeutic pipeline provide a reusable foundation for multiple programs rather than reliance on one asset. Progress across hematology, oncology and other disease areas could diversify future product opportunities and support longer-term strategic value.
Meaningful Equity Cushion
The substantial equity base provides financial cushioning while the company funds costly clinical and research activities. Although losses reduce that support over time, the current capital foundation can help preserve flexibility for development programs and partnership execution.
Experienced Internal CFO Promotion
Promoting an established finance executive supports continuity during a sensitive period of ongoing losses and cash use. His prior company experience and finance background may help maintain institutional knowledge, reporting oversight and disciplined capital management through the transition.
Bears Say
Persistent Cash Burn
Material operating and free-cash-flow deficits show that current activities consume substantial cash rather than funding themselves. If this burn persists, the company may face increasing pressure to preserve spending, secure additional capital or rely more heavily on partnership proceeds.
Severe Unprofitability
Large operating and net losses indicate that the business has not yet converted its scientific platform into sustainable earnings. Persistent negative margins reflect heavy R&D intensity and leave future financial performance dependent on successful development, approvals and commercialization.
Volatile Collaboration-Driven Revenue
Dependence on collaborations makes revenue timing and scale uneven because payments are tied to milestones and partner activity. This reduces predictability of the operating base, complicates planning and leaves reported growth vulnerable to gaps between major development or commercial events.
Crispr Therapeutics AG News
1CG FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
What is Crispr Therapeutics AG’s market cap?
When is Crispr Therapeutics AG’s upcoming earnings report date?
How were Crispr Therapeutics AG’s earnings last quarter?
Is Crispr Therapeutics AG overvalued?
Does Crispr Therapeutics AG pay dividends?
What is Crispr Therapeutics AG’s EPS estimate?
How many shares outstanding does Crispr Therapeutics AG have?
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
What is the TipRanks Smart Score and how is it calculated?
Crispr Therapeutics AG Stock Smart Score
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Samarth Kulkarni
- Employees
- 393
- Website
- www.crisprtx.com
- Address
- Baarerstrasse 14, Zug, ZG, 6300, CH
Crispr Therapeutics AG (1CG) Earnings & Revenues
1CG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 13 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 10 |
